Adverse effects of statins

JAMA - Journal of the American Medical Association

Volumn 317, Issue 10, 2017, Pages 1079-1080

  Malachowski, Stephen J ^a   Quattlebaum, Alexander M ^a   Miladinovic, Branko ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN;

ADVERSE OUTCOME; BRAIN HEMORRHAGE; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; LETTER; LIPID BLOOD LEVEL; MEDICAL HISTORY; RISK ASSESSMENT; RISK FACTOR; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 85015601219     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.0148     Document Type: Letter

References (4)

1. Thompson PD. What to believe and do about statin-associated adverse effects. JAMA. 2016;316(19):1969-1970
2. Wasserstein RL, Lazar NA. The ASA's statement on P values: context, process, and purpose. Am Stat. 2016;70(2):129-133. doi:10.1080/00031305.2016.1154108
3. Nuzzo R. Scientific method: statistical errors. Nature. 2014;506(7487): 150-152
4. Greenland S, Senn SJ, Rothman KJ, et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol. 2016;31(4):337-350